General Information
Ligand DM2 6972
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety ad Efficacy of LGD-6972 in Patients with Type 2 Diabetes Mellitus
| Protocol | L6972-04 |
|---|---|
| Identifier | Site No: 016 |
| UID | 27effa86-6b13-44f5-8548-d3286f8a5d93 |
| Status | Done - Archived |
| Phase | 2 |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2016 |
| NCT Number | - |
| Created | 2016-07-27 11:32 |
| Last Updated | 2016-07-27 11:32 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2016-12-12 | No |
| Enrollment Open | 2016-10-04 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | No | |
| PI Meeting Start | 2016-09-22 | No |
| PI Meeting End | 2016-09-23 | No |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2017-08-01 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | - | No | |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Ligand Pharmaceuticals |
|---|---|
| Division | Ligand Pharmaceuticals |
| Team | Ligand Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Medpace, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
